Lipotropin (sold as a fat-loss peptide)

What lipotropin is

Beta-lipotropin, β-LPH for short, is an endogenous peptide hormone of the pituitary gland and a fragment of the precursor protein POMC. It was first described in 1964. In 1981 it was isolated in pure form from human pituitary glands: 89 amino acids, molecular weight around 11,700. Its fat-releasing potency in the test system matched that of the sheep hormone.

Beta-lipotropin is also a precursor. The intact molecule does not itself act like an opioid, but in the laboratory it gives rise to fragments from position 61 onward, such as met-enkephalin (61-65) and alpha-endorphin (61-76), which do.

This does not tell us what is sold under the name lipotropin. Vendor texts describe a synthetic peptide of 16 amino acids, derived from segment 176-191 of human growth hormone, said to promote fat loss without raising IGF-1. That is the description of HGH fragment 176-191 or of the sequence of AOD-9604, not of beta-lipotropin, which is more than five times as long. The same vendor text refers to beta-lipotropin elsewhere. Sometimes the product is offered as a capsule. We found no independent analysis of which substance is actually contained. Commercially, lipotropin is therefore a name, not a clearly defined active ingredient.

How it is supposed to work

For genuine beta-lipotropin there is a mechanism of action on adipose tissue, described in isolated cells. In rabbit fat cells it released glycerol, a measure of fat breakdown, from 10^-9 mol/l; when inhibitory substances were continuously washed out, 10^-13 to 10^-14 mol/l sufficed. The authors concluded that such peptides could be involved in regulating lipolysis, because the effective amounts are close to blood levels.

Human adipose tissue responds differently. In the classic cell experiment, none of 40 peptide hormones tested stimulated fat release. Only in an improved measurement system did beta-lipotropin have an effect, about as strong as noradrenaline at the same concentration. Two other peptides that worked strongly in animals had no effect in humans. The authors state explicitly that animal results on peptide hormones cannot be transferred to human adipose tissue.

If the product contains the growth hormone fragment, its own body of evidence applies: in animals a described mechanism of action on adipose tissue, in humans no demonstrated weight-loss effect. The details are on the page on HGH fragment 176-191.

What the studies show

Li 1964 and Li and Chung 1981: the hormone

Li described lipotropin in Nature in 1964 as a new active peptide of the pituitary gland. Li and Chung isolated it in pure form from human pituitary glands in 1981: 89 amino acids, molecular weight 11,700, fat-releasing potency equal to that of the sheep hormone. The first 33 building blocks differ markedly from the sheep hormone. Both are structural studies, not studies of use.

Lazarus 1976: precursor of endorphins

Intact beta-lipotropin showed no opioid-like effect in the gut muscle assay or at opioid receptors from rat brain. After incubation with rat brain extract, fragments arose from it that did. The authors classify met-enkephalin (segment 61-65) and alpha-endorphin (61-76) as fragments of beta-lipotropin.

Richter and Schwandt 1985: rabbit fat cells

Beta-lipotropin released glycerol in isolated rabbit fat cells from 10^-9 mol/l. In a flow-through system that continuously removed inhibitory fatty acids and adenosine, the required concentration fell to 10^-13 to 10^-14 mol/l. A cell experiment; no animal and no human was treated.

Richter 1988: human adipose tissue

In the classic experiment with incubated human fat cells, none of 40 peptide hormones stimulated glycerol release. In an improved system with pH-stat titration, beta-lipotropin had a significant effect, comparable with noradrenaline at the same concentration. This is the only finding in human tissue we found, and it comes from the test tube.

Stier 2013: only for the AOD-9604 sequence

The summary of six randomized, double-blind, placebo-controlled trials with AOD-9604 shows no increase in IGF-1, no worsening of glucose tolerance and no antibodies. The paper reports safety, not efficacy. It applies to lipotropin only if exactly this sequence is in the product.

Where the data stop

• No human study. Neither beta-lipotropin nor the fragment described in vendor texts has been tested in humans as a fat-loss agent. In ClinicalTrials.gov we found no study investigating lipotropin as a fat-loss agent.
• Unclear identity. A molecule of 89 and one of 16 amino acids carry the same trade name here. Without laboratory analysis, it is impossible to say which data even apply to the product.
• From cell experiment to the body. Whether a peptide given from outside reaches adipose tissue in an effective amount has not been measured in humans for either variant.
• Marketing with borrowed data. On the gray market, the name of an endogenous hormone is used for a product whose description matches a different molecule. The biology cited does not automatically apply to the product.

Status, approval and legal

Lipotropin is not an approved medicine in Germany, the EU or the US and is sold as a research chemical. Beta-lipotropin is not named either on the WADA Prohibited List 2026 or in the annex of the German Anti-Doping Act.

If the product contains the growth hormone fragment hGH 176-191, that changes: the WADA List 2026 explicitly names AOD-9604 and hGH 176-191 under S2.2.3, prohibited in and out of competition. The German Anti-Doping Act lists both in its annex among the growth hormone fragments. Anyone subject to doping controls therefore cannot rely on the name lipotropin.

Safety

For beta-lipotropin given from outside, there are no safety data in humans. Because it is a precursor of peptides with opioid-like activity, it remains open which cleavage products arise in the body; this has not been studied.

For the AOD-9604 sequence, safety data from six controlled trials are available, without an IGF-1 increase and without worsening of glucose metabolism. They help only if exactly this sequence is contained. Content, purity and identity of research chemicals are not independently tested. For people with diabetes, pregnant and breastfeeding women and people with a history of cancer, there is no data basis.

Sources

• Li CH, Nature 1964 – lipotropin, a new active peptide from the pituitary gland
• Li CH, Chung D, Int J Pept Protein Res 1981 – isolation and sequence of beta-lipotropin from human pituitary glands (89 amino acids)
• Lazarus LH et al., PNAS 1976 – beta-lipotropin as a precursor of endorphins and enkephalins
• Richter WO, Schwandt P, Metabolism 1985 – physiological concentrations of beta-lipotropin stimulate lipolysis in rabbit fat cells
• Richter WO et al., Horm Metab Res Suppl 1988 – lipolysis by peptide hormones in human adipose tissue in vitro
• Stier H et al., J Endocrinol Metab 2013 – safety of AOD9604 in six placebo-controlled trials
• WADA – Prohibited List 2026, S2.2.3 Growth hormone fragments
• German Anti-Doping Act (Anti-Doping-Gesetz), annex – growth hormone fragments (AOD-9604, hGH fragment 176-191)